EU PRIME status for Mereo’s brittle bone drug
London, UK-based Mereo BioPharma’s experimental drug targeting brittle bone disease has been designated PRIME status by the European Medicines Agency (EMA).
Read More
Tag: brittle bone
Trial to test fracture prevention combo in brittle bone patients
The National Institute for Health Research Efficacy and Mechanism Evaluation (EME) Programme is funding a new £1.5 million trial testing a combination of therapies to prevent rapture in patients with brittle bone disease.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
